{"id":34744,"date":"2025-06-04T17:52:45","date_gmt":"2025-06-04T09:52:45","guid":{"rendered":"https:\/\/flcube.com\/?p=34744"},"modified":"2025-06-04T17:52:46","modified_gmt":"2025-06-04T09:52:46","slug":"sanofis-rilzabrutinib-granted-orphan-drug-designation-for-sickle-cell-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34744","title":{"rendered":"Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease"},"content":{"rendered":"\n

France-based Sanofi (NASDAQ: SNY<\/a>) announced that it has received an additional Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its oral Bruton\u2019s tyrosine kinase (BTK) inhibitor rilzabrutinib. This designation is for the treatment of sickle cell disease and follows previous ODDs for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD).<\/p>\n\n\n\n

Rilzabrutinib’s Mechanism and Potential<\/strong>
Rilzabrutinib is designed to reduce vascular occlusion crises in sickle cell disease patients by addressing inflammation and other underlying causes through immune regulation. Preclinical data demonstrated that rilzabrutinib reduced vaso-occlusion and inflammation in transgenic mice models of sickle cell disease.<\/p>\n\n\n\n

Regulatory Review<\/strong>
The drug is currently under regulatory review in the US, EU, and China for its potential use in immune thrombocytopenia (ITP), highlighting its broad therapeutic potential.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD)…<\/p>\n","protected":false},"author":1,"featured_media":34745,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[867,24,147],"class_list":["post-34744","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nasdaq-sny","tag-rare-orphan-disease-drugs","tag-sanofi"],"yoast_head":"\nSanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its oral Bruton\u2019s tyrosine kinase (BTK) inhibitor rilzabrutinib. This designation is for the treatment of sickle cell disease and follows previous ODDs for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34744\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease\" \/>\n<meta property=\"og:description\" content=\"France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its oral Bruton\u2019s tyrosine kinase (BTK) inhibitor rilzabrutinib. This designation is for the treatment of sickle cell disease and follows previous ODDs for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34744\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-04T09:52:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-04T09:52:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0416.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease\",\"datePublished\":\"2025-06-04T09:52:45+00:00\",\"dateModified\":\"2025-06-04T09:52:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744\"},\"wordCount\":150,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0416.webp\",\"keywords\":[\"NASDAQ: SNY\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34744#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34744\",\"name\":\"Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0416.webp\",\"datePublished\":\"2025-06-04T09:52:45+00:00\",\"dateModified\":\"2025-06-04T09:52:46+00:00\",\"description\":\"France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its oral Bruton\u2019s tyrosine kinase (BTK) inhibitor rilzabrutinib. This designation is for the treatment of sickle cell disease and follows previous ODDs for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34744\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0416.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0416.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34744#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease - Insight, China's Pharmaceutical Industry","description":"France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its oral Bruton\u2019s tyrosine kinase (BTK) inhibitor rilzabrutinib. This designation is for the treatment of sickle cell disease and follows previous ODDs for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34744","og_locale":"en_US","og_type":"article","og_title":"Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease","og_description":"France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its oral Bruton\u2019s tyrosine kinase (BTK) inhibitor rilzabrutinib. This designation is for the treatment of sickle cell disease and follows previous ODDs for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD).","og_url":"https:\/\/flcube.com\/?p=34744","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-04T09:52:45+00:00","article_modified_time":"2025-06-04T09:52:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0416.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34744#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34744"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease","datePublished":"2025-06-04T09:52:45+00:00","dateModified":"2025-06-04T09:52:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34744"},"wordCount":150,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34744#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0416.webp","keywords":["NASDAQ: SNY","Rare \/ orphan disease drugs","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34744#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34744","url":"https:\/\/flcube.com\/?p=34744","name":"Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34744#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34744#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0416.webp","datePublished":"2025-06-04T09:52:45+00:00","dateModified":"2025-06-04T09:52:46+00:00","description":"France-based Sanofi (NASDAQ: SNY) announced that it has received an additional Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its oral Bruton\u2019s tyrosine kinase (BTK) inhibitor rilzabrutinib. This designation is for the treatment of sickle cell disease and follows previous ODDs for immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), and IgG4-related disease (IgG4-RD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34744#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34744"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34744#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0416.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0416.webp","width":1080,"height":608,"caption":"Sanofi's Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34744#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Sickle Cell Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0416.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34744"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34744\/revisions"}],"predecessor-version":[{"id":34746,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34744\/revisions\/34746"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34745"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}